The Fort Worth Press - Jaguar Health Reports Approval of All Proposals at March 2025 Special Meeting of Stockholders

USD -
AED 3.672503
AFN 64.999811
ALL 82.324126
AMD 360.540277
ANG 1.790403
AOA 918.000169
ARS 1544.939993
AUD 1.47493
AWG 1.8
AZN 1.698924
BAM 1.769883
BBD 2.014669
BDT 124.715381
BGN 1.77347
BHD 0.378283
BIF 3011.021908
BMD 1
BND 1.291151
BOB 11.678099
BRL 5.666297
BSD 1.000231
BTN 94.44641
BWP 14.015512
BYN 3.004037
BYR 19600
BZD 2.016692
CAD 1.42537
CDF 2315.000184
CHF 0.837958
CLF 0.025469
CLP 1002.376741
CNY 6.67175
CNH 6.673395
COP 3319.97
CRC 449.312832
CUC 1
CUP 24.064952
CVE 100.149904
CZK 22.122964
DJF 178.554905
DKK 6.77912
DOP 60.996961
DZD 137.215041
EGP 53.460841
ERN 15
ETB 164.576405
EUR 0.906405
FJD 2.27435
FKP 0.756889
GBP 0.756398
GEL 2.590269
GGP 0.756889
GHS 11.724953
GIP 0.756889
GMD 74.000357
GNF 8883.748356
GTQ 7.646644
GYD 209.264655
HKD 7.84526
HNL 26.963306
HRK 6.831965
HTG 131.491813
HUF 330.867502
IDR 18235.4
ILS 3.216696
IMP 0.756889
INR 94.245498
IQD 1520.116116
IRR 1913737.498051
ISK 123.929951
JEP 0.756889
JMD 158.434254
JOD 0.709004
JPY 159.657496
KES 130.049851
KGS 87.435501
KHR 4080.00019
KMF 447.000297
KPW 900.00035
KRW 1335.484966
KWD 0.31147
KYD 0.835579
KZT 446.945163
LAK 22570.87132
LBP 89792.715562
LKR 333.505692
LRD 170.463102
LSL 16.951422
LTL 2.952741
LVL 0.60489
LYD 6.463464
MAD 9.936862
MDL 18.213816
MGA 4555.721867
MKD 55.830725
MMK 2100.274506
MNT 3605.662913
MOP 8.103688
MRU 40.552456
MUR 47.619801
MVR 15.400731
MWK 1738.739965
MXN 18.526497
MYR 4.086105
MZN 63.902977
NAD 16.951422
NGN 1343.570244
NIO 36.90298
NOK 10.16413
NPR 151.114437
NZD 1.808483
OMR 0.385095
PAB 1.000231
PEN 3.411802
PGK 4.575679
PHP 63.960117
PKR 277.274459
PLN 3.994115
PYG 6207.891986
QAR 3.64425
RON 4.851895
RSD 106.558993
RUB 82.765228
RWF 1483.467138
SAR 3.82571
SBD 8.097697
SCR 13.874904
SDG 601.490624
SEK 10.06572
SGD 1.287102
SHP 0.752984
SLE 23.050404
SLL 20969.503664
SOS 573.048487
SRD 37.490144
STD 20697.981008
STN 22.225246
SVC 8.773983
SYP 13002.000337
SZL 16.946523
THB 33.874985
TJS 9.249966
TMT 3.5
TND 3.008497
TOP 2.40776
TRY 50.346255
TTD 6.806368
TWD 32.891398
TZS 2655.145825
UAH 45.588969
UGX 4131.053487
UYU 40.541335
UZS 12057.876355
VES 912.87925
VND 25725.5
VUV 120.320092
WST 2.810586
XAF 594.562705
XAG 0.020459
XAU 0.00025782798
XCD 2.70255
XCG 1.807139
XDR 0.707052
XOF 594.562705
XPF 108.324971
YER 236.550281
ZAR 16.93755
ZMK 9001.216069
ZMW 20.500748
ZWL 321.999592
SSP 5945.381189
MXV 2.080549
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Jaguar Health Reports Approval of All Proposals at March 2025 Special Meeting of Stockholders
Jaguar Health Reports Approval of All Proposals at March 2025 Special Meeting of Stockholders

Jaguar Health Reports Approval of All Proposals at March 2025 Special Meeting of Stockholders

Jaguar expects first results in Q2 2025 of proof-of-concept investigator-initiated trials of crofelemer for the rare diseases short bowel syndrome with intestinal failure and microvillus inclusion disease

FDA meeting expected in Q2 2025 on the statistically significant results of the Phase 3 OnTarget trial of crofelemer in the prespecified subgroup of patients with breast cancer

Text size:

SAN FRANCISCO, CA / ACCESS Newswire / March 13, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the voting results of the Company's Special Meeting of Stockholders held on March 13, 2025 (the "Special Meeting").

Two proposals were submitted to and approved by the stockholders of the Company at the Special Meeting. The proposals are described in detail in the Company's definitive proxy statement on Schedule 14A relating to the Special Meeting and supplemental information filed with the Securities and Exchange Commission on February 24, 2025. Stockholders may obtain a free copy of the proxy statement and other documents filed by Jaguar with the SEC at http://www.sec.gov. The proxy statement is also available on the Company's corporate website.

"Jaguar has multiple expected near-term catalysts. The Company is supporting three proof-of-concept (POC) investigator-initiated trials (IIT), and conducting two Phase 2 studies, of crofelemer, our novel plant-based anti-secretory prescription drug, for the rare diseases short bowel syndrome with intestinal failure (SBS-IF) and/or microvillus inclusion disease (MVID) in the US, European Union, and/or Middle East/North Africa regions. The first POC IIT results are expected to be available in the second quarter of 2025, with additional POC IIT results expected throughout 2025. In accordance with the guidelines of specific EU countries, published data from clinical investigations in MVID and SBS-IF could support reimbursed early patient access to crofelemer for these debilitating conditions," Lisa Conte, Jaguar's president and CEO, said. "Additionally, the Company expects that if even just a very small number of MVID patients show benefit with crofelemer, this may potentially allow pathways for regulatory approval in the US and other regions and qualify crofelemer for participation in PRIME, a European Medicines Agency (EMA) program providing enhanced interaction and early dialogue with drug developers of novel medicines targeting unmet medical needs, and in the U.S. Food and Drug Administration's (FDA) Breakthrough Therapies program. If a drug is designated as breakthrough therapy, the FDA will expedite the development and review of the drug."

Jaguar also remains focused on development of crofelemer for cancer therapy-related diarrhea (CTD). As announced, the analysis of the prespecified subgroup of adult patients with breast cancer from the Company's recently conducted Phase 3 prophylactic OnTarget clinical trial for diarrhea in adult patients with solid tumors receiving targeted therapy with or without standard chemotherapy indicate that crofelemer achieved statistically significant results in this subgroup. These results were the subject of a December 11, 2024 poster presentation at the San Antonio Breast Cancer Symposium. The Company has requested a meeting with the FDA to discuss the results of OnTarget in breast cancer patients and potential pathways to bring crofelemer to this patient population as efficiently as possible, and expects the meeting to take place in the second quarter of 2025.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit www.napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Magdalena Biosciences, visit magdalenabiosciences.com

Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that the first POC IIT results may be available in Q2 2025 for crofelemer for SBS-IF and MVID, Jaguar's expectation that, in accordance with the guidelines of specific EU countries, published data from clinical investigations in MVID and SBS-IF could support reimbursed early patient access to crofelemer for these debilitating conditions, Jaguar's expectation that, if even just a very small number of MVID patients show benefit with crofelemer, this may potentially allow approval in the United States for crofelemer for MVID and qualify crofelemer for participation in PRIME for this indication and in the FDA's Breakthrough Therapies program, and Jaguar's expectation that a meeting with the FDA will take place in Q2 2025. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Source: Jaguar Health, Inc.

Contact:

[email protected]

Jaguar-JAGX

SOURCE: Jaguar Health, Inc.



View the original press release on ACCESS Newswire

J.Ayala--TFWP